Document Detail

The valve patient and pregnancy.
MedLine Citation:
PMID:  18939912     Owner:  NLM     Status:  MEDLINE    
Pregnancy causes a significant and sustained increase in cardiac output that may be poorly tolerated in cases of underlying heart disease. Valvular stenosis is often poorly tolerated and may require intervention during pregnancy, percutaneous intervention being the favored option. Conversely, regurgitant valve diseases are generally well-tolerated. Pregnancy in patients who have previously undergone prosthetic valve replacement raises specific problems linked to anticoagulant therapy. The choice is difficult between oral anticoagulation, which carries a risk of embryopathy, and heparin therapy, which is safer for the fetus but is associated with a high thromboembolic risk for the mother. The diversity of cases highlights the need for appropriate evaluation of heart disease before pregnancy and close follow-up by specialized teams.
Bernard Iung
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  6     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-10-22     Completed Date:  2009-01-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1249-58     Citation Subset:  IM    
Cardiology Department, Bichat Hospital, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / adverse effects,  therapeutic use
Balloon Dilatation / methods
Cardiac Output / physiology
Heart Valve Diseases / drug therapy,  physiopathology,  surgery*
Heart Valve Prosthesis*
Pregnancy Complications, Cardiovascular / drug therapy,  surgery*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Management of high defibrillation threshold.
Next Document:  Development of cardiovascular bypass grafts: endothelialization and applications of nanotechnology.